Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gender-Based Dosing For Insomnia Drugs Dissected In NEJM

This article was originally published in The Pink Sheet Daily

Executive Summary

CDER officials explain the rationale behind new labeling on zolpidem-containing immediate- and controlled-release products that halves the recommended dose for women. Labeling changes include a new precaution against next-day driving following use of Sanofi’s Ambien CR.

You may also be interested in...



Ambien Not Sleepwalking Through Scrutiny; Label Warnings Updated

Sanofi's sleeping pill has been revised once again in an update that also limits the recommended dosing.

Insomnia Drug Development Programs Must Include Driving Studies, FDA Says

Agency will require driving simulation studies for all new sleep aids and is asking sponsors of currently approved products to conduct such trials. FDA is directing zolpidem-containing product manufacturers to make labeling changes based, in part, on driving data submitted for Transcept’s Intermezzo.

Transcept Gains Long-Delayed Approval Of Intermezzo

Indication for insomnia characterized by middle-of-the-night awakening followed by difficulty returning to sleep is a first.

Topics

Related Companies

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel